£30k-a-year prostate cancer drug too expensive for NHS

The drug abiraterone cuts the risk of men dying within three years by a third, but tablets are only on the NHS for patients who've had chemotherapy or stopped responding to standard drugs.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Abstract223Ra-dichloride is a bone-seeking targeted alpha ( α)-emitting approved for bone metastases in prostate cancer. Here, we report a case of therapy-related acute promyelocytic leukemia (t-APL) following administration of223Ra, showing some evidence of a causative relationship. A patient with metastatic prostate cancer received therapy with223Ra, with 6 injections of the radiopharmaceutical at a standard dose of 55  kBq/kg at 4-week intervals for a cumulative administered activity of 26.3 MBq. PET/CT with18F-methylcholine repeated 1  month after the conclusion of223Ra was negative. After 8  ...
Source: Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
ConclusionTreating anterior prostate cancer lesions with focal HIFU may be less effective compared to posterior tumours.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Enzalutamide improves 5-year survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer, but increases the risk of fatal adverse events, according to final results from the PREVAIL trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Publication date: Available online 2 July 2020Source: European UrologyAuthor(s): Francesco Massari, Veronica Mollica
Source: European Urology - Category: Urology & Nephrology Source Type: research
Circulating tumor cells (CTCs) are considered to be promising biomarkers in malignant diseases. Recently, molecular profiles of CTCs in prostate cancer (PCa) and the role of CTCs in neoadjuvant chemotherapy and transurethral resections of bladder cancer (BCa) are intensely studied. However, localized PCa and non-muscle-invasive BCa are less investigated and discussed. Moreover, the benefit and feasibility of clinical applications of CTCs should be critically questioned and reevaluated. This review focuses mainly on clinical issues and lesser on methodologies, and summarizes the quintessence of available works dealing with ...
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Conclusion: PERCIST 1.0 may provide significant prognostic information for patients with mCRPC undergoing systemic chemotherapy, particularly when incorporated with PSA treatment response criteria.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: Induction of hypoxic stress responses through inhibition of gp130 represents a novel approach to design effective anticancer treatments in combination with standard-of-care chemotherapy in OC and the efficacy reported here strongly supports their clinical development.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Glucocorticoids are used as co-medication with chemotherapy for solid tumors to reduce inflammation as well as cytotoxic side effects and are effective in easing symptoms related to chemotherapy. However, emerging evidence suggests that glucocorticoids may contribute to failure of chemotherapy and tumor progression of castration resistant prostate cancer (CRPC). Thus, in recent years, glucocorticoid signaling pathway has become an important therapeutic target for CRPC. Understanding the exact mechanism of GR actions in CRPC is still work in progress. There are studies suggesting that GR expression can be upregulated follow...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Researchers at UCLA Jonsson Comprehensive Cancer Center will soon begin studying the pre-surgery use of cryoablation as a potential early adjuvant therapy for patients with pleural mesothelioma. The pilot study will measure immune system stimulation through local tumor infiltration in hopes of extending patient survival in the future. Cryoablation, also known as cryotherapy or cryosurgery, freezes localized tumors with liquid nitrogen or argon gas. It has been proven effective in killing tumor cells with extreme cold. It is currently used on kidney, liver and prostate cancers, but its use in priming a person’s own i...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
PMID: 32592623 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Prostate Cancer